This “UK Healthcare Outlook 2022” provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in UK. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of UK.
As per the analysis, UK has a globally unique health and life sciences ecosystem. NHS offers a national research and evidence gathering platform with unique data and clinical insights. Track record of scientific breakthroughs is driving the next generation of life-changing treatments, technologies and services. There are a number of regulatory bodies in place which monitor and assess the quality of health services provided by public and private providers. Quality issues are addressed in a variety of methods. There as certain disadvantageous side effects to the government's participation in the healthcare system. Their active role in healthcare weakens the functionality of market mechanisms. In addition, the tight control undertaken in regards to medical expenses has resulted in a lack of medical resources, such as equipment, doctors and nurses in public hospitals.
United Kingdom, island country located off the northwestern coast of mainland Europe. The United Kingdom comprises the whole of the island of Great Britain - which contains England, Wales, and Scotland - as well as the northern portion of the island of Ireland. The capital is London, which is among the world's leading commercial, financial, and cultural centers. It has 66.87 million people, distributed on a territory of 242,495 square kilometers. In 2019, the rate of GDP growth in the United Kingdom was at around 1.41 percent compared to the previous year.
The United Kingdom provides public healthcare to all permanent residents. Healthcare coverage is free at the point of need, and is paid for by general taxation. About 18% of a citizen's income tax goes towards healthcare, which is about 4.5% of the average citizen's income. Overall, around 8.4% of the UK's gross domestic product is spent on healthcare. UK also has a growing private healthcare sector that is still much smaller than the public sector.
The UK has a government-sponsored public healthcare system called the NHS. The NHS is composed of a group of UK publicly funded healthcare systems. It encompasses the National Health System (England), NHS Scotland, NHS Wales and Northern Ireland Health and Social Care. Under this scheme, people are entitled to healthcare but still have the option of purchasing private health insurance. The NHS Plan promises more patient capacity and information, more hospitals and beds, more nurses and doctors, considerably shorter waiting times for services and better treatment for elderly patients and tighter NHS guidelines.
Social care services are a shared responsibility between the local NHS and the local government's Directors of Social Services, and falls under the guidance of the Department of Health. According to the World Health Organization, government funding covers 85% of healthcare expenditure in the UK. The remaining 15% is covered by private sector.
The UK is home to GlaxoSmithKline and AstraZeneca, respectively the world's fifth- and sixth-largest pharmaceutical companies. Foreign companies with a major presence in the UK pharmaceutical industry include Pfizer, Novartis, Hoffmann-La Roche and Eisai. One in five of the world's biggest-selling prescription drugs were developed in the UK. The most notable event for the pharma industry so far has been the update of the government's life sciences strategy, which lays out plans for the sector's future. This June 2016, it's been four years since UK citizens accepted a UK referendum to leave the EU (i.e., Brexit). Whether or not the United Kingdom would have an agreement in shaping its future relationship with the EU is still on the negotiation table as the deadline for achieving an agreement looms. After a multi-year process to exit the EU, the UK officially exited the EU on January 31, 2020 and entered into an 11-month transition period until the end of 2020 to work out or not its future relationship with the EU. During the transition period, EU law and rules are still applicable across the UK, and the UK remains part of the EU single market and custom union. The UK will formally exit the EU in all ways by the end of the transition period on December 31, 2020.
An important development for life science businesses is the publication of the Medicines and Medical Devices Bill. As expected, this draft legislation will provide for the UK Government to take over the rulebook for human and veterinary medicines, clinical trials and medical devices after the end of the transition period on 31st December 2020. Currently very closely harmonized at EU level, the legislation is not expected to diverge rapidly from EU law. However, there are clear signals in the Bill and Explanatory Notes that a separate approach is likely to evolve.
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in UK.
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in UK.
Market access section of the UK Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
Over the past year, investment into the UK healthcare real estate market has grown ever more international. The biggest deal of 2019 saw Medical Properties Trust (MPT) acquire 30 private hospitals for billions of Euro, making it the largest real estate deal of the year. The deal was part of Circle Health's acquisition of BMI Healthcare, which comprised 54 hospitals in total. There is driven demand from a broader range of investors in recent years, from opportunistic private equity funds to risk-averse pension providers. UK performed well when it came to quality of care and access to care. The UK also ranked first in efficiency, which was measured by examining total national spending on healthcare as a percentage of GDP, as well as the amount spent on healthcare administration and insurance. Quality of care one of the key focuses of the NHS. Indeed, one of their stated goals is to enhance the quality and safety standards of health and social care services.
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
As per the analysis, UK has a globally unique health and life sciences ecosystem. NHS offers a national research and evidence gathering platform with unique data and clinical insights. Track record of scientific breakthroughs is driving the next generation of life-changing treatments, technologies and services. There are a number of regulatory bodies in place which monitor and assess the quality of health services provided by public and private providers. Quality issues are addressed in a variety of methods. There as certain disadvantageous side effects to the government's participation in the healthcare system. Their active role in healthcare weakens the functionality of market mechanisms. In addition, the tight control undertaken in regards to medical expenses has resulted in a lack of medical resources, such as equipment, doctors and nurses in public hospitals.
UK Healthcare Outlook
United Kingdom, island country located off the northwestern coast of mainland Europe. The United Kingdom comprises the whole of the island of Great Britain - which contains England, Wales, and Scotland - as well as the northern portion of the island of Ireland. The capital is London, which is among the world's leading commercial, financial, and cultural centers. It has 66.87 million people, distributed on a territory of 242,495 square kilometers. In 2019, the rate of GDP growth in the United Kingdom was at around 1.41 percent compared to the previous year.
The United Kingdom provides public healthcare to all permanent residents. Healthcare coverage is free at the point of need, and is paid for by general taxation. About 18% of a citizen's income tax goes towards healthcare, which is about 4.5% of the average citizen's income. Overall, around 8.4% of the UK's gross domestic product is spent on healthcare. UK also has a growing private healthcare sector that is still much smaller than the public sector.
The UK has a government-sponsored public healthcare system called the NHS. The NHS is composed of a group of UK publicly funded healthcare systems. It encompasses the National Health System (England), NHS Scotland, NHS Wales and Northern Ireland Health and Social Care. Under this scheme, people are entitled to healthcare but still have the option of purchasing private health insurance. The NHS Plan promises more patient capacity and information, more hospitals and beds, more nurses and doctors, considerably shorter waiting times for services and better treatment for elderly patients and tighter NHS guidelines.
Social care services are a shared responsibility between the local NHS and the local government's Directors of Social Services, and falls under the guidance of the Department of Health. According to the World Health Organization, government funding covers 85% of healthcare expenditure in the UK. The remaining 15% is covered by private sector.
UK Industry Overview Chapter
Pharmaceutical
The UK is home to GlaxoSmithKline and AstraZeneca, respectively the world's fifth- and sixth-largest pharmaceutical companies. Foreign companies with a major presence in the UK pharmaceutical industry include Pfizer, Novartis, Hoffmann-La Roche and Eisai. One in five of the world's biggest-selling prescription drugs were developed in the UK. The most notable event for the pharma industry so far has been the update of the government's life sciences strategy, which lays out plans for the sector's future. This June 2016, it's been four years since UK citizens accepted a UK referendum to leave the EU (i.e., Brexit). Whether or not the United Kingdom would have an agreement in shaping its future relationship with the EU is still on the negotiation table as the deadline for achieving an agreement looms. After a multi-year process to exit the EU, the UK officially exited the EU on January 31, 2020 and entered into an 11-month transition period until the end of 2020 to work out or not its future relationship with the EU. During the transition period, EU law and rules are still applicable across the UK, and the UK remains part of the EU single market and custom union. The UK will formally exit the EU in all ways by the end of the transition period on December 31, 2020.
Medical Device
An important development for life science businesses is the publication of the Medicines and Medical Devices Bill. As expected, this draft legislation will provide for the UK Government to take over the rulebook for human and veterinary medicines, clinical trials and medical devices after the end of the transition period on 31st December 2020. Currently very closely harmonized at EU level, the legislation is not expected to diverge rapidly from EU law. However, there are clear signals in the Bill and Explanatory Notes that a separate approach is likely to evolve.
Legislation in this area has previously been updated at EU level, with the changes flowing through into UK law. The Medicines and Medical Devices Bill will allow the Health Secretary to take over that task. The Bill proposes similar powers to amend or supplement the medical devices legislation. Of course, the existing EU directives in this area are due to be replaced by two new Regulations:
- Regulation 2017/745 on medical devices (applicable from 26 May 2020)
- Regulation 2017/746 on in vitro diagnostic medical devices (applicable from 26 May 2022).
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in UK.
UK Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in UK.
UK: Market Access
Market access section of the UK Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
Over the past year, investment into the UK healthcare real estate market has grown ever more international. The biggest deal of 2019 saw Medical Properties Trust (MPT) acquire 30 private hospitals for billions of Euro, making it the largest real estate deal of the year. The deal was part of Circle Health's acquisition of BMI Healthcare, which comprised 54 hospitals in total. There is driven demand from a broader range of investors in recent years, from opportunistic private equity funds to risk-averse pension providers. UK performed well when it came to quality of care and access to care. The UK also ranked first in efficiency, which was measured by examining total national spending on healthcare as a percentage of GDP, as well as the amount spent on healthcare administration and insurance. Quality of care one of the key focuses of the NHS. Indeed, one of their stated goals is to enhance the quality and safety standards of health and social care services.
UK: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
- Overview of the pharmaceutical and medical device markets
- An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market
UK Report Insights
- UK - Healthcare Outlook
- UK - Healthcare Assessment
- UK - Market Access
- UK - Healthcare Market Perspectives
- UK - Analyst View
Key Questions Answered
- What are business strategies and trends shaping and driving the UK healthcare market?
- What are reimbursement and regulatory policies, pharmaceutical and medical device market segments and companies likely to impact the UK healthcare market in the future?
- How to organize sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment and strategic partnership?
- How to identify, understand and capitalize on the opportunities and challenges in the UK healthcare market?
Key Players
- The Harley Street Clinic
- Portland Hospital
- Ramsay Health Care UK
- Synergy Health
- Nuffield Health
- GlaxoSmithKline
- Oxford BioLabs
- Spire Healthcare
- Allied Healthcare
- Circle Health Ltd
Table of Contents
1. Key Insights2. UK at a Glance6. UK PESTLE Analysis7. Driver and Barriers9. References10. Publisher Capabilities11. Disclaimer12. About the Publisher
3. Executive Summary
4. Assessment
5. Market Access
8. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- The Harley Street Clinic
- Portland Hospital
- Ramsay Health Care UK
- Synergy Health
- Nuffield Health
- GlaxoSmithKline
- Oxford BioLabs
- Spire Healthcare
- Allied Healthcare
- Circle Health Ltd
